Skip to content

Application of stereotactic central ablation radiotherapy ( SCART ) plus or without intensity-modulated radiotherapy combined with immunotherapy in refractory bulky tumors

Application of stereotactic central ablation radiotherapy ( SCART ) plus or without intensity-modulated radiotherapy combined with immunotherapy in refractory bulky tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089713
Enrollment
Unknown
Registered
2024-09-13
Start date
2024-09-25
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignancies

Interventions

groupA (SCART+IMRT+ICI, Radiotherapy and immunotherapy):None
groupB (SCART+ICI):None

Sponsors

Hainan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1, =18 years of age; 2. malignant tumors confirmed by cells or pathology; 3. Primary, recurrent or metastatic tumors, = 5 cm in diameter, or involving important organs, in patients who cannot undergo surgery, failed first-line treatment, or refused chemotherapy; 4. ECOG =60 points 5. Survival is expected to be =3 months 6. No serious comorbidities (bone marrow, liver and kidney function, coagulation function, heart function) 7. the elution period of previous anti-tumor therapy was >4 weeks; 8. sign written informed consent; 9. agree to collect biological specimens of tissue or blood) for standby;

Exclusion criteria

Exclusion criteria: 1, received radiotherapy at the same site within 3 months; 2. in pregnancy or lactation; 3. Diffuse metastases of the central nervous system (brain, meninges, spinal cord) 4. severe comorbidities (severe infection, bone marrow depression, cardio-cerebrovascular disease, persistent or intractable epilepsy; severe cardiac insufficiency, coagulation disorder, active hemorrhage, electrolyte disturbances); 5. KPS <60 points; 6. Any arterial thrombosis, embolism, or ischemia that occurred within 6 months before enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; 7. previous history of mental illness, alcohol abuse, drug use, or substance abuse;

Design outcomes

Primary

MeasureTime frame
objective relieate rate (ORR);Local Control Rate (LCR);

Secondary

MeasureTime frame
progress-free survival ;overall survival ;safety;side-effect;

Countries

China

Contacts

Public ContactYunxiu Luo

Hainan Cancer Hospital

375237661@qq.com+86 138 8611 4385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026